Designing a Rational Biomarker Strategy for Antigen-Specific Immune Tolerance Based on a Detailed Understanding of Mechanisms of Action
11:00 am - Wednesday 24th March 2027
- Mapping a drug’s mechanism of action in detail, making it possible to anticipate how it will perform in the clinic before trial results arrive, and replacing a trial-and-error approach with one supported by evidence
- Precise biomarker panels built on a strong level of mechanistic detail, allowing trial teams to monitor a drug’s biological activity in real time, and confirm it is performing as expected well ahead of efficacy readouts
- Parvus’s peptide-MHC nanomedicine program which offers a study with safety, tolerability, and pharmacodynamic data showing how a well-designed biomarker strategy can demonstrate drug activity in humans
